Caris Life Sciences
Provider of clinical molecular profiling and AI/ML analytics for oncology. Operates CLIA-validated high-throughput laboratories that perform whole-genome, whole-exome and whole-transcriptome sequencing, proteomic and computational pathology analyses to produce clinician-facing reports, support therapy selection, enable clinical trial matching and collaborate with biopharma on biomarker and target discovery.
Industries
Nr. of Employees
Very Large (1000+)
Caris Life Sciences
Patents
Products
Whole-genome-based multi-cancer early detection blood test
Blood-based assay using ultra-deep whole-genome sequencing and machine learning analytics to detect cancer-associated signals and provide tissue-of-origin probabilities; offered as a CLIA-validated laboratory-developed test where available.
Comprehensive tissue profiling via simultaneous whole-exome and whole-transcriptome sequencing
Tissue assay performing concurrent whole-exome and whole-transcriptome sequencing with ancillary protein and targeted assays to support treatment selection and companion diagnostic reporting.
Hybrid tissue assay capturing DNA and RNA (LDT)
Laboratory-developed tissue assay that simultaneously captures DNA and RNA and incorporates algorithmic signatures to support diagnosis and therapy selection while conserving tissue.
Tissue-based comprehensive profiling package (DNA/RNA/IHC/ISH)
Integrated tissue profiling that includes sequencing, immunohistochemistry and in situ hybridization to assess DNA, RNA and protein markers for clinical decision support and trial matching.
Whole Exome Sequencing
A high-throughput, next generation sequencing-based assay analyzing the whole human exome of approximately 23,000+ DNA genes to detect DNA point mutations, insertions, deletions, copy number alterations, and genomic signatures.
Tumor Mutational Burden (TMB) by Whole Exome Sequencing
Tumor Mutational Burden (TMB) by Whole Exome Sequencing measures the total number of mutations that result in altered proteins, serving as a pan-tumor biomarker that indicates whether a cancer may respond to immunotherapies. The Caris TMB assay quantifies non-synonymous, somatic mutations per megabase.
Whole-genome-based multi-cancer early detection blood test
Blood-based assay using ultra-deep whole-genome sequencing and machine learning analytics to detect cancer-associated signals and provide tissue-of-origin probabilities; offered as a CLIA-validated laboratory-developed test where available.
Comprehensive tissue profiling via simultaneous whole-exome and whole-transcriptome sequencing
Tissue assay performing concurrent whole-exome and whole-transcriptome sequencing with ancillary protein and targeted assays to support treatment selection and companion diagnostic reporting.
Hybrid tissue assay capturing DNA and RNA (LDT)
Laboratory-developed tissue assay that simultaneously captures DNA and RNA and incorporates algorithmic signatures to support diagnosis and therapy selection while conserving tissue.
Tissue-based comprehensive profiling package (DNA/RNA/IHC/ISH)
Integrated tissue profiling that includes sequencing, immunohistochemistry and in situ hybridization to assess DNA, RNA and protein markers for clinical decision support and trial matching.
Whole Exome Sequencing
A high-throughput, next generation sequencing-based assay analyzing the whole human exome of approximately 23,000+ DNA genes to detect DNA point mutations, insertions, deletions, copy number alterations, and genomic signatures.
Tumor Mutational Burden (TMB) by Whole Exome Sequencing
Tumor Mutational Burden (TMB) by Whole Exome Sequencing measures the total number of mutations that result in altered proteins, serving as a pan-tumor biomarker that indicates whether a cancer may respond to immunotherapies. The Caris TMB assay quantifies non-synonymous, somatic mutations per megabase.
Services
Laboratory-based molecular profiling services integrating DNA and RNA sequencing with protein-level assays to inform therapy selection and clinical decision making.
Blood-based screening workflow using whole-genome sequencing and machine learning analytics to detect cancer-associated signals and provide tissue-origin guidance in adults.
Whole-blood sequencing service that analyzes plasma cell-free nucleic acids together with matched white blood cells to reduce false positives and identify somatic, clonal hematopoiesis and incidental germline variants.
High-coverage whole-genome sequencing service intended to provide a single comprehensive genomic assay for diagnosis, risk stratification and treatment planning in myeloid malignancies.
Collaborative research agreements combining large-scale clinico-genomic datasets with wet-lab validation to identify and validate therapeutic targets for biopharmaceutical partners.
Patient-to-trial matching and rapid site activation services that leverage an oncology site network to accelerate enrollment and site readiness for clinical trials.
Laboratory-based molecular profiling services integrating DNA and RNA sequencing with protein-level assays to inform therapy selection and clinical decision making.
Blood-based screening workflow using whole-genome sequencing and machine learning analytics to detect cancer-associated signals and provide tissue-origin guidance in adults.
Whole-blood sequencing service that analyzes plasma cell-free nucleic acids together with matched white blood cells to reduce false positives and identify somatic, clonal hematopoiesis and incidental germline variants.
High-coverage whole-genome sequencing service intended to provide a single comprehensive genomic assay for diagnosis, risk stratification and treatment planning in myeloid malignancies.
Collaborative research agreements combining large-scale clinico-genomic datasets with wet-lab validation to identify and validate therapeutic targets for biopharmaceutical partners.
Patient-to-trial matching and rapid site activation services that leverage an oncology site network to accelerate enrollment and site readiness for clinical trials.
Expertise Areas
- Clinical molecular profiling
- Liquid biopsy and cell-free nucleic acid analysis
- Next-generation sequencing-based oncology diagnostics
- AI/ML analytics applied to clinico-genomic data
Key Technologies
- Whole-genome sequencing (WGS)
- Whole-exome sequencing (WES)
- Whole-transcriptome sequencing (WTS)
- Ultra-deep cell-free DNA sequencing
News & Updates
Participation and booth presence at the CAP 2026 meeting in Las Vegas.
Participation and booth presence at the ESMO 2026 congress in Madrid.
Multi-year collaboration to identify and validate novel oncology targets using a repository of solid tumor samples and integrated tissue- and data-driven discovery workflows.
Quarterly financial report noting revenue growth driven by molecular profiling services and disclosure of testing volumes, margins and guidance.
Announcement of a $310M financing to support expansion of molecular profiling, R&D and biopharma initiatives.
Press release announcing a significant growth equity financing to expand the precision medicine platform and support product and network expansion, including clinical trial solutions.
Participation and booth presence at the CAP 2026 meeting in Las Vegas.
Participation and booth presence at the ESMO 2026 congress in Madrid.
Multi-year collaboration to identify and validate novel oncology targets using a repository of solid tumor samples and integrated tissue- and data-driven discovery workflows.
Quarterly financial report noting revenue growth driven by molecular profiling services and disclosure of testing volumes, margins and guidance.
Announcement of a $310M financing to support expansion of molecular profiling, R&D and biopharma initiatives.
Press release announcing a significant growth equity financing to expand the precision medicine platform and support product and network expansion, including clinical trial solutions.